Scientists are a step closer to a cure for Ebola after two of four drugs in a clinical trial were found to significantly increase survival rates, the US health authority co-funding the research said.
The study began last November in the Democratic Republic of Congo, but its current phase will now be stopped and all future patients switched over to the two treatments that have shown positive results, the US National Institutes of Health said in a statement.
“The preliminary results in 499 study participants indicated that individuals receiving REGN-EB3 or mAb114 had a greater chance of survival compared to participants in the other two arms.”
Patients who were receiving the two drugs that are being discontinued, Zmapp and remdesivir, will now have the option at the discretion of their treating physician to receive the treatments that have been shown to work.
The NIH added the final analysis of the data would occur in late September or early October, after which the complete results would be submitted for publication in peer-reviewed medical literature.
The NIH, Democratic Republic of Congo health authorities and the World Health Organisation hailed the “extraordinary team of individuals who have worked under extremely difficult conditions to carry out this study,” as well as the patients and their families.
“It is through this type of rapidly implemented, rigorous research that we can quickly and definitively identify the best treatments and incorporate them into the Ebola outbreak response,” they said.
Jeremy Farrar, director of Britain’s Wellcome Trust research charity, said the development would “undoubtedly save lives,” adding: “Thanks to this trial, we are starting to understand which treatments to offer to patients in this and future outbreaks.”
More than 1,800 people have died in eastern Democratic Republic of Congo since Ebola broke out there in August last year.
The virus is transmitted to people from wild animals, then spreads among humans through direct contact with the blood or other secretions of infected people or with surfaces contaminated with their fluids, according to the World Health Organisation.
The average fatality rate for people with the disease is around 50 percent.